House & Home
Wed, July 29, 2009Tue, July 28, 2009Mon, July 27, 2009Fri, July 24, 2009Thu, July 23, 2009Wed, July 22, 2009Tue, July 21, 2009Mon, July 20, 2009Fri, July 17, 2009Thu, July 16, 2009Wed, July 15, 2009Tue, July 14, 2009Mon, July 13, 2009Fri, July 10, 2009Thu, July 9, 2009Wed, July 8, 2009Tue, July 7, 2009Mon, July 6, 2009Fri, July 3, 2009Thu, July 2, 2009Wed, July 1, 2009Tue, June 30, 2009Mon, June 29, 2009Sun, June 28, 2009Fri, June 26, 2009Thu, June 25, 2009Wed, June 24, 2009Tue, June 23, 2009Mon, June 22, 2009Fri, June 19, 2009Thu, June 18, 2009Wed, June 17, 2009Tue, June 16, 2009Mon, June 15, 2009Sun, June 14, 2009Fri, June 12, 2009Thu, June 11, 2009Wed, June 10, 2009Tue, June 9, 2009Mon, June 8, 2009Sun, June 7, 2009Fri, June 5, 2009Thu, June 4, 2009Wed, June 3, 2009Tue, June 2, 2009Mon, June 1, 2009Fri, May 29, 2009Thu, May 28, 2009Wed, May 27, 2009Tue, May 26, 2009Mon, May 25, 2009Fri, May 22, 2009Thu, May 21, 2009Wed, May 20, 2009Tue, May 19, 2009Mon, May 18, 2009Sun, May 17, 2009Fri, May 15, 2009Thu, May 14, 2009Wed, May 13, 2009Tue, May 12, 2009Mon, May 11, 2009CNS Response, Inc.: CNS Response Closes $1 Million Bridge Financing and Completes Clinical Trial Enrollment
//house-home.news-articles.net/content/2009/06/2 .. ing-and-completes-clinical-trial-enrollment.html
Published in House and Home on Tuesday, June 23rd 2009 at 9:21 GMT, Last Modified on 2009-06-23 09:22:16 by Market WireCOSTA MESA, CA--(Marketwire - June 23, 2009) - CNS Response, Inc. (
"This financing comes at a critical time for CNS Response, providing both the resources to complete the treatment-resistant depression trial and drive wider clinical use of Referenced-EEG®," stated George Carpenter, Chief Executive Officer of CNS Response. "John Pappajohn has financed numerous healthcare companies, from Caremark to Quantum Health, and has introduced many healthcare innovations through his commercialization expertise and financial leadership."
Over the past two months the company has obtained two bridge loans totaling $1.2 million. Details pertaining to the bridge loans are available in the Form 8-Ks filed with the SEC.
CNS Response also announced that it has completed enrollment at 14 study sites for its treatment-resistant depression (TRD) clinical trial. This puts the company on track to complete the trial in September and release top-line results before year-end.
"Completion of our clinical trial is an important milestone for CNS Response," said President and Chief Medical Officer Daniel Hoffman. "Physicians using Referenced-EEG are achieving better patient outcomes and, according to the United BioSource study, Referenced-EEG already offers superior evidence for treatment-resistant depression. Our current clinical trial will bring this technology to the attention of the nation's top academic and clinical psychiatrists."
About CNS Response
Today, most physicians are able to base treatment on objective test data, such as EKGs, MRIs, blood tests, etc. Broadly speaking, such advances have not yet come to those physicians practicing psychiatry.
CNS Response has developed a patented data-analysis capability that, with the help of a simple, non-invasive EEG, will analyze a patient's brain waves and compare the results to an extensive patient outcomes database. The process produces an rEEG® report providing a psychiatrist with guidance to personalize medication regimens for a patient, based on the patient's own brain physiology. To read more about the benefits this patented technology provides physicians, patients and insurers, please visit the CNS Response website, [ www.cnsresponse.com ].
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
